Since the present results and previous findings indicated that the MDM4 protein could be overexpressed, due most likely to post-transcriptional regulation, even in the absence of gene amplification and/or transcript overexpression (Figure 1A) [20], an immunohistochemical biomarker analysis of MDM4 expression in surgical specimens of meningiomas may facilitate the selection of patients more likely to benefit from the CEP-1347 treatment in its future clinical application. The gene discussed is MDM4; the disease is meningioma.